The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was the first-ever large-scale anti-inflammatory prevention trial targeting Alzheimer’s disease.
Objective:
The overall goal of this study was to evaluate predictive blood biomarker profiles that identified individuals most likely to be responders on NSAID treatment or placebo at 12 and 24 months.
Methods:
Baseline (n = 193) and 12-month (n = 562) plasma samples were assayed. The predictive biomarker profile was generated using SVM analyses with response on treatment (yes/no) as the outcome variable.
Results:
Baseline (AUC = 0.99) and 12-month (AUC = 0.99) predictive biomarker profiles were highly accurate in predicting response on Celecoxib arm at 12 and 24 months. The baseline (AUC = 0.95) and 12-month (AUC = 0.9) predictive biomarker profile predicting response on Naproxen were also highly accurate at 12 and 24 months. The baseline (AUC = 0.93) and 12-month (AUC = 0.99) predictive biomarker profile was also highly accurate in predicting response on placebo. As with our prior work, the profiles varied by treatment arm.
Conclusions:
The current results provide additional support for a precision medicine model for treating and preventing Alzheimer’s disease.
HurdMD, MartorellP, DelavandeA, MullenKJ, LangaKM (2013) Monetary costs of dementia in the United States. N Engl J Med368, 1326–1334.
2.
(2020) 2020 Alzheimer’s disease facts and figures. Alzheimers Dement16, 391–460.
3.
O’BryantSE, ZhangF, JohnsonLA, HallJ, EdwardsM, GrammasP, OhE, LyketsosCG, RissmanRA (2018) A precision medicine model for targeted NSAID therapy in Alzheimer’s disease. J Alzheimers Dis66, 97–104.
4.
O’BryantSE, ZhangF, PetersenM, JohnsonL, HallJ, RissmanRA (2021) A precision medicine approach to treating Alzheimer’s disease using rosiglitazone therapy: A biomarker analysis of the REFLECT Trials. J Alzheimers Dis81, 557–568.
5.
LyketsosCG, BreitnerJCS, GreenRC, MartinBK, MeinertC, PiantadosiS, SabbaghM (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology68, 1800–1808.
6.
HampelH, O’BryantSE, CastrilloJI, RitchieC, RojkovaK, BroichK, BendaN, NisticòR, FrankRA, DuboisB, Escott-PriceV, ListaS (2016) PRECISION MEDICINE - The Golden Gate for detection, treatment and prevention of Alzheimer’s disease. J Prev Alzheimers Dis3, 243–259.
7.
HampelH, O’BryantSE, DurrlemanS, YounesiE, RojkovaK, Escott-PriceV, CorvolJC, BroichK, DuboisB, ListaS (2017) A Precision Medicine Initiative for Alzheimer’s disease: The road ahead to biomarker-guided integrative disease modeling. Climacteric20, 107–118.
8.
WeilAR (2018) Precision medicine. Health Aff37, 687–687.
JørgensenJT (2015) Companion diagnostics: The key to personalized medicine. Foreword. Expert Rev Mol Diagn15, 153–156.
12.
SlamonDJ, Leyland-JonesB, ShakS, FuchsH, PatonV, BajamondeA, FlemingT, EiermannW, WolterJ, PegramM, BaselgaJ, NortonL (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med344, 783–792.
13.
O’BryantSE, PetersenM, ZhangF, JohnsonL, MasonD, HallJ (2022) Analysis of a precision medicine approach to treating Parkinson’s disease: Analysis of the DATATOP study. Parkinsonism Relat Disord94, 15–21.
14.
FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource Glossary. Food and Drug Administration, Silver Springs, MD.
15.
O’BryantSE, EdwardsM, JohnsonL, HallJ, VillarrealAE, BrittonGB, QuicenoM, CullumCM, Graff-RadfordNR (2016) A blood screening test for Alzheimer’s disease. Alzheimers Dement3, 83–90.
16.
O’BryantSE, EdwardsM, ZhangF, JohnsonLA, HallJ, KurasY, ScherzerCR (2019) Potential two-step proteomic signature for Parkinson’s disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimers Dement11, 374–382.
17.
O’BryantSE, XiaoG, ZhangF, EdwardsM, GermanDC, YinX, ComoT, ReischJ, HuebingerRM, Graff-RadfordN, DicksonD, BarberR, HallJ, O’SuilleabhainP, GrammasP (2014) Validation of a serum screen for Alzheimer’s disease across assay platforms, species, and tissues. J Alzheimers Dis42, 1325–1335.
18.
O’BryantSE, FermanTJ, ZhangF, HallJ, PedrazaO, WszolekZK, ComoT, JulovichD, MattevadaS, JohnsonLA, EdwardsM, HallJ, Graff-RadfordNR (2019) . A proteomic signature for dementia with Lewy bodies. Alzheimers Dement11, 270–276.
BemillerSM, McCrayTJ, AllanK, FormicaSV, XuG, WilsonG, Kokiko-CochranON, CrishSD, Lasagna-ReevesCA, RansohoffRM, LandrethGE, LambBT (2017) TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener12, 74.
24.
MetaxasA, VaitheeswaranR, JensenKT, ThygesenC, IlkjaerL, DarveshS, FinsenB (2018) Reduced serotonin transporter levels and inflammation in the midbrain raphe of 12 month old APPswe/PSEN1dE9 mice. Curr Alzheimer Res15, 420–428.
25.
LeeDY, HwangCJ, ChoiJY, ParkMH, SongMJ, OhKW, HanSB, ParkWK, ChoHY, ChoSY, ParkHB, SongMJ, HongJT (2017) KRICT-9 inhibits neuroinflammation, amyloidogenesis and memory loss in Alzheimer’s disease models. Oncotarget8, 68654–68667.
26.
SundaramJR, PooreCP, SulaimeeNHB, PareekT, CheongWF, WenkMR, PantHC, FrautschySA, LowCM, KesavapanyS (2017) Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer’s disease. J Alzheimers Dis60, 1429–1442.
27.
SchmidtR, SchmidtH, CurbJD, MasakiK, WhiteLR, LaunerLJ (2002) Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol52, 168–174.
28.
AnthonyJC, BreitnerJC, ZandiPP, MeyerMR, JurasovaI, NortonMC, StoneSV (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study. Neurology54, 2066–2071.
29.
LaiKSP, LiuCS, RauA, LanctôtKL, KöhlerCA, PakoshM, CarvalhoAF, HerrmannN (2017) Peripheral inflammatory markers in Alzheimer’s disease: A systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry88, 876–882.
30.
EtminanM, GillS, SamiiA (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: Systematic review and meta-analysis of observational studies. BMJ327, 128.
31.
AisenPS, SchaferKA, GrundmanM, PfeifferE, SanoM, DavisKL, FarlowMR, JinS, ThomasRG, ThalLJ; Alzheimer’s Disease Cooperative Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA289, 2819–2826.
32.
O’BryantSE, ZhangF, PetersenM, HallJR, JohnsonLA, YaffeK, MasonD, BraskieM, BarberRA, RissmanRA, MapstoneM, MielkeMM, TogaAW; HABLE Study Team (2022) A blood screening tool for detecting mild cognitive impairment and Alzheimer’s disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimers Dement18, 77–87.
